Cell Source Inc
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of ly… Read more
Cell Source Inc (CLCS) - Total Liabilities
Latest total liabilities as of September 2024: $19.21 Million USD
Based on the latest financial reports, Cell Source Inc (CLCS) has total liabilities worth $19.21 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cell Source Inc - Total Liabilities Trend (2012–2023)
This chart illustrates how Cell Source Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cell Source Inc Competitors by Total Liabilities
The table below lists competitors of Cell Source Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TVI Pacific Inc
PINK:TVIPF
|
USA | $5.81 Million |
|
Barrister Energy LLC
PINK:CJAX
|
USA | $589.86K |
|
Choice Development Inc
TW:9929
|
Taiwan | NT$998.37 Million |
|
Inswave Systems Co., Ltd.
KQ:450520
|
Korea | ₩13.48 Billion |
|
Hammer Metals Limited
F:6HM
|
Germany | €1.02 Million |
|
Pinnacle Bancshares Inc
PINK:PCLB
|
USA | $341.03 Million |
|
Procorp S.A.B. de C.V
MX:PROCORPB
|
Mexico | MX$986.91 Million |
Liability Composition Analysis (2012–2023)
This chart breaks down Cell Source Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 72.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cell Source Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cell Source Inc (2012–2023)
The table below shows the annual total liabilities of Cell Source Inc from 2012 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $15.81 Million | +21.18% |
| 2022-12-31 | $13.04 Million | +28.64% |
| 2021-12-31 | $10.14 Million | +20.72% |
| 2020-12-31 | $8.40 Million | +43.42% |
| 2019-12-31 | $5.86 Million | +15.08% |
| 2018-12-31 | $5.09 Million | 0.00% |
| 2017-12-31 | $5.09 Million | -21.15% |
| 2016-12-31 | $6.45 Million | +5.35% |
| 2015-12-31 | $6.13 Million | +56.80% |
| 2014-12-31 | $3.91 Million | +53104.86% |
| 2013-12-31 | $7.34K | +44.01% |
| 2012-12-31 | $5.10K | -- |